Iikura Y, Naspitz C K, Mikawa H, Talaricoficho S, Baba M, Sole D, Nishima S
Department of Allergology, National Pediatric Hospital, Tokyo, Japan.
Ann Allergy. 1992 Mar;68(3):233-6.
To evaluate the prophylactic effect of ketotifen against the onset of asthma we selected 121 infants with atopic dermatitis, without any history suggestive of asthma (cough and/or wheezing). Sixty-one children received ketotifen twice daily. Those who weighed less than 14 kg received 0.8 mg; 14 kg or more, 1.2 mg. Sixty children, a placebo syrup indistinguishable from the active syrup. Both groups were followed for 1 year, with bimonthly evaluations. The criteria for onset of asthma were two different episodes of wheezing treated with bronchodilator drugs. Both groups were comparable regarding age, sex, weight, onset, and duration of atopic dermatitis and age at the onset of asthma. During the 1 year study, asthma was observed in eight children of the ketotifen group (13.1%) and in 25 children of the placebo group (41.6%) (P less than .001). Side effects were negligible and routine laboratory tests disclosed no significant alterations. Ketotifen is a very useful drug for prevention of asthma in children with atopic dermatitis and total IgE more than 50 IU/mL.
为评估酮替芬对哮喘发作的预防作用，我们选取了121名患有特应性皮炎且无任何哮喘病史（咳嗽和/或喘息）的婴儿。61名儿童每日服用两次酮替芬。体重不足14千克的儿童服用0.8毫克；14千克及以上的儿童服用1.2毫克。60名儿童服用与活性糖浆无差异的安慰剂糖浆。两组均随访1年，每两个月评估一次。哮喘发作的标准为使用支气管扩张剂治疗的两次不同喘息发作。两组在年龄、性别、体重、特应性皮炎的起病和病程以及哮喘起病时的年龄方面具有可比性。在为期1年的研究中，酮替芬组有8名儿童（13.1%）出现哮喘，安慰剂组有25名儿童（41.6%）出现哮喘（P小于0.001）。副作用可忽略不计，常规实验室检查未发现明显异常。对于特应性皮炎且总IgE超过50 IU/mL的儿童，酮替芬是预防哮喘的非常有用的药物。
